The 30 trillion cells that self-assemble into a human being originate from the pluripotent stem cells in the inner cell mass of a human blastocyst. The discovery of induced pluripotent stem cells (iPSCs) makes it possible to approximate various aspects of this natural developmental process artificially by generating materials that can be used in invasive mechanistic studies of virtually all human conditions. In Parkinson’s disease, instructions computed by the basal ganglia to control voluntary motor functions break down, leading to widespread rhythmic bursting activities in the basal ganglia and beyond. It is thought that these oscillatory neuronal activities, which disrupt aperiodic neurotransmission in a normal brain, may reduce information content in the instructions for motor control. Using midbrain neuronal cultures differentiated from iPSCs of Parkinson’s disease patients with parkin mutations, we find that parkin mutations cause oscillatory neuronal activities when dopamine D1-class receptors are activated. This system makes it possible to study the molecular basis of rhythmic bursting activities in Parkinson’s disease. Further development of stem cell models of Parkinson’s disease will enable better approximation of the situation in the brain of Parkinson’s disease patients. In this review, I will discuss what has been found in the past about the pathophysiology of motor dysfunction in Parkinson’s disease, especially oscillatory neuronal activities and how stem cell technologies may transform our abilities to understand the pathophysiology of Parkinson’s disease.
SenderRFuchsSMiloR.Revised estimates for the number of human and bacteria cells in the body. PLoS Biol2016;
14:e1002533
2.
BradleyAEvansMKaufmanMHRobertsonE.Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines. Nature1984;
309:255–6
3.
CapecchiMR.Altering the genome by homologous recombination. Science1989;
244:1288–92
4.
ThomsonJAItskovitz-EldorJShapiroSSWaknitzMASwiergielJJMarshallVSJonesJM.Embryonic stem cell lines derived from human blastocysts. Science1998;
282:1145–7
5.
TakahashiKTanabeKOhnukiMNaritaMIchisakaTTomodaKYamanakaS.Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell2007;
131:861–72
6.
PuJJiangHZhangBFengJ.Redefining Parkinson's disease research using induced pluripotent stem cells. Curr Neurol Neurosci Rep2012;
12:392–8
7.
ObesoJAStamelouMGoetzCGPoeweWLangAEWeintraubDBurnDHallidayGMBezardEPrzedborskiSLehericySBrooksDJRothwellJCHallettMDeLongMRMarrasCTannerCMRossGWLangstonJWKleinCBonifatiVJankovicJLozanoAMDeuschlGBergmanHTolosaERodriguez-ViolanteMFahnSPostumaRBBergDMarekKStandaertDGSurmeierDJOlanowCWKordowerJHCalabresiPSchapiraAHVStoesslAJ.Past, present, and future of Parkinson's disease: a special essay on the 200th anniversary of the shaking palsy. Mov Disord2017;
32:1264–310
8.
DawsonTMKoHSDawsonVL.Genetic animal models of Parkinson's disease. Neuron2010;
66:646–61
9.
KempJMPowellTP.The structure of the caudate nucleus of the cat: light and electron microscopy. Philos Trans R Soc Lond, B, Biol Sci1971;
262:383–401
10.
BolamJPHanleyJJBoothPABevanMD.Synaptic organisation of the basal ganglia. J Anatomy2000;
196:527–42
11.
GerfenCREngberTMMahanLCSuselZChaseTNMonsmaFJJr.SibleyDR.D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science1990;
250:1429–32
12.
GerfenCRSurmeierDJ.Modulation of striatal projection systems by dopamine. Annu Rev Neurosci2011;
34:441–66
13.
MatsudaWFurutaTNakamuraKCHiokiHFujiyamaFAraiRKanekoT.Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J Neurosci2009;
29:444–53
14.
AlbinRLYoungABPenneyJB.The functional anatomy of basal ganglia disorders. Trends Neurosci1989;
12:366–75
15.
SurmeierDJDingJDayMWangZShenW.D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci2007;
30:228–35
16.
KravitzAVFreezeBSParkerPRKayKThwinMTDeisserothKKreitzerAC.Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature2010;
466:622–6
17.
WichmannTDeLongMRGuridiJObesoJA.Milestones in research on the pathophysiology of Parkinson's disease. Mov Disord2011;
26:1032–41
18.
PanigrahiBMartinKALiYGravesARVollmerAOlsonLMenshBDKarpovaAYDudmanJT.Dopamine is required for the neural representation and control of movement vigor. Cell2015;
162:1418–30
19.
BergmanHWichmannTDeLongMR.Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science1990;
249:1436–8
20.
LimousinPPollakPBenazzouzAHoffmannDLe BasJFBroussolleEPerretJEBenabidAL.Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet1995;
345:91–5
21.
DeLongMRBenabidAL.Discovery of high-frequency deep brain stimulation for treatment of Parkinson disease: 2014 lasker award. JAMA2014;
312:1093–4
22.
WichmannTDostrovskyJO.Pathological basal ganglia activity in movement disorders. Neuroscience2011;
198:232–44
23.
BrownPWilliamsD.Basal ganglia local field potential activity: character and functional significance in the human. Clin Neurophysiol2005;
116:2510–9
24.
TinkhauserGPogosyanATanHHerzDMKuhnAABrownP.Beta burst dynamics in Parkinson's disease off and on dopaminergic medication. Brain2017;
140:2968–81
25.
WilsonCJBevanMD.Intrinsic dynamics and synaptic inputs control the activity patterns of subthalamic nucleus neurons in health and in Parkinson's disease. Neuroscience2011;
198:54–68
26.
HammondCBergmanHBrownP.Pathological synchronization in Parkinson's disease: networks, models and treatments. Trends Neurosci2007;
30:357–64
27.
RazAFeingoldAZelanskayaVVaadiaEBergmanH.Neuronal synchronization of tonically active neurons in the striatum of normal and parkinsonian primates. J Neurophysiol1996;
76:2083–8
28.
RazAVaadiaEBergmanH.Firing patterns and correlations of spontaneous discharge of pallidal neurons in the normal and the tremulous 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine vervet model of parkinsonism. J Neurosci2000;
20:8559–71
29.
BergmanHWichmannTKarmonBDeLongMR.The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol1994;
72:507–20
30.
CassidyMMazzonePOlivieroAInsolaATonaliPDiL, VBrownP.Movement-related changes in synchronization in the human basal ganglia. Brain2002;
125:1235–46
31.
LitvakVEusebioAJhaAOostenveldRBarnesGFoltynieTLimousinPZrinzoLHarizMIFristonKBrownP.Movement-related changes in local and long-range synchronization in Parkinson's disease revealed by simultaneous magnetoencephalography and intracranial recordings. J Neurosci2012;
32:10541–53
32.
GoldbergJARokniUBoraudTVaadiaEBergmanH.Spike synchronization in the cortex/basal-ganglia networks of parkinsonian primates reflects global dynamics of the local field potentials. J Neurosci2004;
24:6003–10
33.
SurmeierDJMercerJNChanCS.Autonomous pacemakers in the basal ganglia: who needs excitatory synapses anyway?Curr Opin Neurobiol2005;
15:312–8
34.
WilsonCJ.Oscillators and oscillations in the basal ganglia. Neuroscientist2015;
21:530–9
35.
WilsonCJ.Active decorrelation in the basal ganglia. Neuroscience2013;
250:467–82
36.
KitadaTAsakawaSHattoriNMatsumineHYamamuraYMinoshimaSYokochiMMizunoYShimizuN.Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature1998;
392:605–8
37.
NuytemansKTheunsJCrutsMVan BroeckhovenC.Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat2010;
31:763–80
38.
AsakawaSHattoriNShimizuAShimizuYMinoshimaSMizunoYShimizuN.Analysis of eighteen deletion breakpoints in the parkin gene. Biochem Biophys Res Commun2009;
389:181–6
39.
ClarkLNWangYKarlinsESaitoLMejia-SantanaHHarrisJLouisEDCoteLJAndrewsHFahnSWatersCFordBFruchtSOttmanRMarderK.Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology2006;
67:1786–91
40.
MarderKWangYAlcalayRNMejia-SantanaHTangMXLeeARaymondDMirelmanASaunders-PullmanRClarkLOzeliusLOrr-UrtregerAGiladiNBressmanS.Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox ashkenazi jewish LRRK2 consortium. Neurology2015;
85:89–95
LesageSLeuteneggerALIbanezPJaninSLohmannEDurrABriceA.LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. Am J Hum Genet2005;
77:330–2
43.
HernandezDGReedXSingletonAB.Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. J Neurochem2016;
139(Suppl 1):59–74
44.
FerreiraMMassanoJ.An updated review of Parkinson's disease genetics and clinicopathological correlations. Acta Neurol Scand2017;
135:273–84
45.
JiangHRenYYuenEYZhongPGhaediMHuZAzabdaftariGNakasoKYanZFengJ.Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells. Nat Commun2012;
3:668
46.
JiangHJiangQLiuWFengJ.Parkin suppresses the expression of monoamine oxidases. J Biol Chem2006;
281:8591–9
47.
RenYJiangHMaDNakasoKFengJ.Parkin degrades estrogen-related receptors to limit the expression of monoamine oxidases. Hum Mol Genet2011;
20:1074–83
48.
ShihJCChenKRiddMJ.Monoamine oxidase: from genes to behavior. Annu Rev Neurosci1999;
22:197–217
49.
HuZPuJJiangHZhongPQiuJLiFWangXZhangBYanZFengJ.Generation of naivetropic induced pluripotent stem cells from Parkinson's disease patients for high-efficiency genetic manipulation and disease modeling. Stem Cells Dev2015;
24:2591–604
50.
RenYJiangHHuZFanKWangJJanoschkaSWangXGeSFengJ.Parkin mutations reduce the complexity of neuronal processes in iPSC-derived human neurons. Stem Cells2015;
33:68–78
51.
RenYLiuWJiangHJiangQFengJ.Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J Biol Chem2005;
280:34105–12
52.
RenYJiangHYangFNakasoKFengJ.Parkin protects dopaminergic neurons against microtubule-depolymerizing toxins by attenuating microtubule-associated protein kinase activation. J Biol Chem2009;
284:4009–17
53.
YangFJiangQZhaoJRenYSuttonMDFengJ.Parkin stabilizes microtubules through strong binding mediated by three independent domains. J Biol Chem2005;
280:17154–62
54.
ZhongPHuZJiangHYanZFengJ.Dopamine induces oscillatory activities in human midbrain neurons with parkin mutations. Cell Rep2017;
19:1033–44
55.
TrempeJFChenCXGrenierKCamachoEMKozlovGMcPhersonPSGehringKFonEA.SH3 domains from a subset of BAR proteins define a ubl-binding domain and implicate parkin in synaptic ubiquitination. Mol Cell2009;
36:1034–47
56.
CaoMMilosevicIGiovediSDe CamilliP.Upregulation of parkin in endophilin mutant mice. J Neurosci2014;
34:16544–9
57.
HuynhDPScolesDRNguyenDPulstSM.The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. Hum Mol Genet2003;
12:2587–97
58.
ZhangYGaoJChungKKHuangHDawsonVLDawsonTM.Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci U S A2000;
97:13354–9
59.
SassoneJSerrattoGValtortaFSilaniVPassafaroMCiammolaA.The synaptic function of parkin. Brain2017;
140:2265–72
60.
ChenTWWardillTJSunYPulverSRRenningerSLBaohanASchreiterERKerrRAOrgerMBJayaramanVLoogerLLSvobodaKKimDS.Ultrasensitive fluorescent proteins for imaging neuronal activity. Nature2013;
499:295–300
PuJFrescasDZhangBFengJ.Utilization of TALEN and CRISPR/Cas9 technologies for gene targeting and modification. Exp Biol Med2015;
240:1065–70
63.
LancasterMARennerMMartinCAWenzelDBicknellLSHurlesMEHomfrayTPenningerJMJacksonAPKnoblichJA.Cerebral organoids model human brain development and microcephaly. Nature2013;
501:373–9
64.
QianXNguyenHNSongMMHadionoCOgdenSCHammackCYaoBHamerskyGRJacobFZhongCYoonKJJeangWLinLLiYThakorJBergDAZhangCKangEChickeringMNauenDHoCYWenZChristianKMShiPYMaherBJWuHJinPTangHSongHMingGL.Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure. Cell2016;
165:1238–54
65.
WuJPlatero-LuengoASakuraiMSugawaraAGilMAYamauchiTSuzukiKBogliottiYSCuelloCMoralesVMOkumuraDLuoJVilarinoMParrillaISotoDAMartinezCAHishidaTSanchez-BautistaSMartinez-MartinezMLWangHNohalezAAizawaEMartinez-RedondoPOcampoAReddyPRocaJMagaEAEstebanCRBerggrenWTNunezDELajaraJGuillenIGuillenPCampistolJMMartinezEARossPJIzpisua BelmonteJC.Interspecies chimerism with mammalian pluripotent stem cells. Cell2017;
168:473–86
66.
YangYLiuBXuJWangJWuJShiCXuYDongJWangCLaiWZhuJXiongLZhuDLiXYangWYamauchiTSugawaraALiZSunFLiXLiCHeADuYWangTZhaoCLiHChiXZhangHLiuYLiCDuoSYinMShenHBelmonteJCDengH.Derivation of pluripotent stem cells with in vivo embryonic and extraembryonic potency. Cell2017;
169:243–57
67.
KobayashiTYamaguchiTHamanakaSKato-ItohMYamazakiYIbataMSatoHLeeYSUsuiJKniselyASHirabayashiMNakauchiH.Generation of rat pancreas in mouse by interspecific blastocyst injection of pluripotent stem cells. Cell2010;
142:787–99
HuZLiHJiangHRenYYuXQiuJStablewskiABZhangBBuckMJFengJ.Transient inhibition of mTOR in human pluripotent stem cells enables robust formation of mouse-human chimeric embryos. Sci Adv2020;
6:eaaz0298
70.
HyunI.From naive pluripotency to chimeras: a new ethical challenge?Development2015;
142:6–8
71.
KimmelmanJHyunIBenvenistyNCaulfieldTHeslopHEMurryCESippDStuderLSugarmanJDaleyGQ.Policy: global standards for stem-cell research. Nature2016;
533:311–3
